An antisense oligonucleotide and its use in the treatment of ovarian cancer
By correcting the abnormal splicing of ovarian cancer cells with antisense oligonucleotides that target CDK2 alternative splicing, downregulating CDK2 expression, and activating the apoptosis pathway, this approach addresses the problem of chemotherapy resistance in ovarian cancer and provides a new treatment strategy. In particular, it exhibits a synergistic effect when used in combination with PARP inhibitors.
CN120424929BActive Publication Date: 2026-06-26SHANDONG UNIV
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SHANDONG UNIV
- Filing Date
- 2025-04-30
- Publication Date
- 2026-06-26
Smart Images
Figure CN120424929B_ABST
Abstract
The application discloses an antisense oligonucleotide and application thereof in treatment of ovarian cancer, and belongs to the technical field of ovarian cancer gene therapy. The antisense oligonucleotide has a nucleotide sequence as shown in SEQ ID NO. 1. In vitro experimental results show that the antisense oligonucleotide can retard cell cycle and induce cell apoptosis in a human ovarian cancer cell line. When the antisense oligonucleotide is combined with a PARP inhibitor olaparib, a significant synergistic anti-tumor effect is exhibited, which indicates that the antisense oligonucleotide has the potential to overcome the drug resistance problem of the PARP inhibitor. In a C57BL / 6 mouse subcutaneous transplantation tumor model, intratumoral injection of ASO1 can significantly slow down tumor growth and reduce tumor volume. The application provides a scheme with a brand-new action mechanism for treatment of ovarian cancer, and especially exhibits important clinical value for platinum-resistant or recurrent ovarian cancer patients.
Need to check novelty before this filing date? Find Prior Art